Treatment of superficial carcinoma of the bladder.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D011882:Radiotherapy, High-Energy; D013852:Thiotepa / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D004317:Doxorubicin; D013852:Thiotepa